Literature DB >> 22933045

Estrogen treatment for acromegaly.

Ilan Shimon1, Ariel Barkan.   

Abstract

Estrogens have been used in patients with acromegaly since the 1930-1940s, suppressing plasma IGF-1 levels and improving clinical signs and symptoms of acromegaly. Estrogens antagonize GH function at the post-receptor level, inhibiting GH signaling, thus decreasing GH-induced hepatic IGF-1 synthesis. We report our experience with four female patients with active acromegaly, naïve to medical treatment or inadequately controlled by somatostatin receptor ligands (SRLs) or the GH-receptor antagonist. Adding estrogen treatment (contraceptive pills or transdermal estrogen patches) to their ongoing medical treatment, suppressed IGF-1 significantly in all patients, achieving hormonal remission in three of them. We review the available data on the use of estrogens and selective estrogen receptor modulators in acromegaly, and their mechanisms of action. Estrogens could be an alternative, inexpensive adjuvant treatment for females with active acromegaly, who are only partially responding to SRLs or to the GH-receptor antagonist.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22933045     DOI: 10.1007/s11102-012-0426-4

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  49 in total

Review 1.  Optimizing the dose of hormone replacement therapy.

Authors:  Valerie Montgomery Rice
Journal:  Int J Fertil Womens Med       Date:  2002 Sep-Oct

2.  Acromegaly.

Authors:  G J HAMWI; T G SKILLMAN; K C TUFTS
Journal:  Am J Med       Date:  1960-10       Impact factor: 4.965

Review 3.  Clinical relevance of systemic and local IGF-I.

Authors:  Shoshana Yakar; Patricia Pennisi; Yiping Wu; Hong Zhao; Derek LeRoith
Journal:  Endocr Dev       Date:  2005

Review 4.  Modern oral contraceptives and cardiovascular disease.

Authors:  L Rosenberg; J R Palmer; M I Sands; D Grimes; U Bergman; J Daling; A Mills
Journal:  Am J Obstet Gynecol       Date:  1997-09       Impact factor: 8.661

5.  Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women.

Authors:  P Burman; A G Johansson; A Siegbahn; B Vessby; F A Karlsson
Journal:  J Clin Endocrinol Metab       Date:  1997-02       Impact factor: 5.958

6.  Estroprogestinic pill normalizes IGF-I levels in acromegalic women.

Authors:  R Cozzi; M Barausse; S Lodrini; G Lasio; R Attanasio
Journal:  J Endocrinol Invest       Date:  2003-04       Impact factor: 4.256

7.  Cabergoline in acromegaly: a renewed role for dopamine agonist treatment?

Authors:  R Cozzi; R Attanasio; M Barausse; D Dallabonzana; P Orlandi; N Da Re; V Branca; G Oppizzi; D Gelli
Journal:  Eur J Endocrinol       Date:  1998-11       Impact factor: 6.664

8.  Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2.

Authors:  K C Leung; N Doyle; M Ballesteros; K Sjogren; C K W Watts; T H Low; G M Leong; R J M Ross; K K Y Ho
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-27       Impact factor: 11.205

9.  Mechanism of estrogenic action in acromegaly.

Authors:  E Schwartz; E Echemendia; M Schiffer; V A Panariello
Journal:  J Clin Invest       Date:  1969-02       Impact factor: 14.808

Review 10.  Guidelines for acromegaly management: an update.

Authors:  S Melmed; A Colao; A Barkan; M Molitch; A B Grossman; D Kleinberg; D Clemmons; P Chanson; E Laws; J Schlechte; M L Vance; K Ho; A Giustina
Journal:  J Clin Endocrinol Metab       Date:  2009-02-10       Impact factor: 5.958

View more
  7 in total

Review 1.  Pharmacological treatment of acromegaly: its place in the overall therapeutic approach.

Authors:  Evgenia Korytnaya; Ariel Barkan
Journal:  J Neurooncol       Date:  2014-01-18       Impact factor: 4.130

Review 2.  Estrogens and selective estrogen receptor modulators in acromegaly.

Authors:  Felipe H Duarte; Raquel S Jallad; Marcello D Bronstein
Journal:  Endocrine       Date:  2016-10-04       Impact factor: 3.633

3.  IGF-I levels reflect hypopituitarism severity in adults with pituitary dysfunction.

Authors:  Amit Tirosh; Yoel Toledano; Hiba Masri-Iraqi; Yoav Eizenberg; Gloria Tzvetov; Dania Hirsch; Carlos Benbassat; Eyal Robenshtok; Ilan Shimon
Journal:  Pituitary       Date:  2016-08       Impact factor: 4.107

Review 4.  Estrogen and selective estrogen receptor modulators (SERMs) for the treatment of acromegaly: a meta-analysis of published observational studies.

Authors:  Jennifer C Stone; Justin Clark; Ross Cuneo; Anthony W Russell; Suhail A R Doi
Journal:  Pituitary       Date:  2014-06       Impact factor: 4.107

Review 5.  A practical approach to acromegaly management in Latin America.

Authors:  Marcello D Bronstein; Oscar D Bruno; Alin Abreu; Ruth Mangupli; Moisés Mercado
Journal:  Pituitary       Date:  2014-01       Impact factor: 4.107

6.  Associations of GNAS Mutations with Surgical Outcomes in Patients with Growth Hormone-Secreting Pituitary Adenoma.

Authors:  Hyein Jung; Kyungwon Kim; Daham Kim; Ju Hyung Moon; Eui Hyun Kim; Se Hoon Kim; Cheol Ryong Ku; Eun Jig Lee
Journal:  Endocrinol Metab (Seoul)       Date:  2021-03-23

Review 7.  Current therapies and mortality in acromegaly.

Authors:  S Găloiu; C Poiană
Journal:  J Med Life       Date:  2015 Oct-Dec
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.